Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | FBP1 | P09467 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | FOS | P01100 | 1/20 | 0.42 |
| ▸ | JUN | P05412 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2345016 | 1.00 | NFE2L2 (0.48) | NFE2L2CYP2A6FBP1MAPTRELA | |
| SCHEMBL3715295 | 0.78 | CYP2A6 (0.44) | CYP2A6ALDH1A1KMT2A | |
| SCHEMBL3715296 | 0.78 | CYP2A6 (0.44) | CYP2A6ALDH1A1KMT2A | |
| SCHEMBL3051230 | 0.76 | APP (0.52) | MAPTRELAALDH1A1RAB9ANPC1 | |
| SCHEMBL11042248 | 0.76 | APP (0.43) | CA1 | |
| SCHEMBL2342481 | 0.76 | CYP1A2 (0.50) | NFE2L2CYP2A6FBP1MAPTALOX5 | |
| SCHEMBL196959 | 0.76 | APP (0.52) | NFE2L2FBP1MAPTRELACA1 | |
| SCHEMBL11042246 | 0.76 | APP (0.43) | CA1 | |
| SCHEMBL10839054 | 0.76 | NFE2L2 (0.48) | NFE2L2CYP2A6FBP1MAPTRELA | |
| SCHEMBL2339964 | 0.76 | CYP2C19 (0.42) | CYP2A6MAPTALDH1A1CYP3A4HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090022729-A1 | METHODS AND COMPOSITIONS FOR TREATING CARDIAC DYSFUNCTIONS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-01-22 | — | — | US | claimed |
| WO-2008128038-A2 | METHODS AND COMPOSITIONS FOR TREATING CARDIAC DYSFUNCTIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2008-10-23 | — | — | WO | claimed |
| US-4410696-A | Antitumor and immunosuppressive 4-carbamoylimidazolium-5-olate derivatives | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1983-10-18 | — | — | US | claimed |
| EP-0075629-A1 | Imidazole derivatives, their preparation, and their pharmaceutical compositions | Sumitomo Chemical Industries Ltd. (JP) | 1983-04-06 | — | — | EP | claimed |
| US-4369309-A | HYPOTENSIVE AGENTS; UASODILATION; CARDIOVASCULAR DISORDERS | SS PHARMACEUTICAL CO., LTD. (JP) | 1983-01-18 | — | — | US | claimed |
| EP-3239139-B1 | CHEMICAL SYNTHESIS AND ANTI-TUMOR AND ANTI-METASTATIC EFFECTS OF DUAL FUNCTIONAL CONJUGATE | NINGBO COMBIREG PHARMACEUTICAL TECH CO LTD (CN) | 2020-10-28 | — | — | EP | disclosed |
| EP-3239139-A1 | CHEMICAL SYNTHESIS AND ANTI-TUMOR AND ANTI-METASTATIC EFFECTS OF DUAL FUNCTIONAL CONJUGATE | Shenzhen Salubris Pharmaceuticals Co., Ltd (CN) | 2017-11-01 | — | — | EP | disclosed |
| EP-2257297-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF ACNE, SEBORRHOEA AND SEBHORROEIC DERMATITIS, OR FOR REDUCING SEBUM SECRETION | MIMETICA PTY LTD (AU) | 2017-10-18 | — | — | EP | disclosed |
| EP-2612857-B1 | CHEMICAL SYNTHESIS AND ANTI-TUMOR AND ANTI-METASTATIC EFFECTS OF DUAL FUNCTIONAL CONJUGATE | SHENZHEN SALUBRIS PHARM CO LTD (CN) | 2017-07-26 | — | — | EP | disclosed |
| US-9340517-B2 | Methods of modulating the activity of the MC5 receptor and treatment of conditions related to this receptor | MIMETICA PTY LTD (AU) | 2016-05-17 | — | — | US | disclosed |
| US-9085605-B2 | Chemical synthesis and anti-tumor and anti-metastatic effects of dual functional conjugate | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (CN) | 2015-07-21 | — | — | US | disclosed |
| EP-2257534-B1 | 3-AMINOALKYL-1,4-DIAZEPAN-2-ONE MELANOCORTIN-5 RECEPTOR ANTAGONISTS | MIMETICA PTY LTD (AU) | 2013-11-06 | — | — | EP | disclosed |
| US-4361515-A | Antihyperlipemic dihydro-ML-236B derivatives, their preparation and use | SANKYO COMPANY, LIMITED (JP) | 1982-11-30 | — | — | US | disclosed |
| US-4352928-A | ANTIINFLAMMATORY, HYPOGLYCEMIC, ANTICOAGULANT, ANOREXIGENIC, SEROTONIN EFFEC | MITSUBISHI YUKA PHARMACEUTICAL CO., LTD. (JP) | 1982-10-05 | — | — | US | disclosed |
| US-4337244-A | COMPRISING A FIBRINOLYTIC ENZYME BLOCKED BY AN END GROUP REMOVABLE BY HYDROLYSIS | BEECHAM GROUP LIMITED (GB) | 1982-06-29 | — | — | US | disclosed |
| US-4285932-A | Enzyme derivatives for use in the treatment of venous thrombosis | BEECHAM GROUP LIMITED (GB) | 1981-08-25 | — | — | US | disclosed |
| EP-0028489-A1 | Enzyme derivatives, and their preparation | BEECHAM GROUP PLC (GB) | 1981-05-13 | — | — | EP | disclosed |
| US-4259350-A | PROTECTING DEGRADABLE ORGANIC MATERIAL FROM FUNGAL OR INSECT ATTACK | SANKYO COMPANY LIMITED (JP) | 1981-03-31 | — | — | US | disclosed |
| EP-0022481-A1 | 5,6-Alkylenepyrimidine derivatives, processes for preparing the same and pharmaceutical compositions | Mitsubishi Yuka Pharmaceutical Co., Ltd. (JP) | 1981-01-21 | — | — | EP | disclosed |
| EP-0009879-A1 | Enzyme derivatives for use in the treatment of venous thrombosis, compositions containing them and their preparation | BEECHAM GROUP PLC (GB) | 1980-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090022729-A1 | METHODS AND COMPOSITIONS FOR TREATING CARDIAC DYSFUNCTIONS | TNNI3, MYLK2, FABP3 | NFE2L2 937/4885CYP2A6 4837/4885FBP1 1250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.